1. Home
  2. SKE vs BLLN Comparison

SKE vs BLLN Comparison

Compare SKE & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skeena Resources Limited

SKE

Skeena Resources Limited

HOLD

Current Price

$30.28

Market Cap

3.8B

ML Signal

HOLD

BLLN

BillionToOne Inc.

N/A

Current Price

$98.77

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKE
BLLN
Founded
1979
2016
Country
Canada
United States
Employees
170
713
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.9B
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SKE
BLLN
Price
$30.28
$98.77
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$126.71
AVG Volume (30 Days)
509.1K
702.9K
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$46.29
Revenue Next Year
$37,573.35
$30.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.12
$61.96
52 Week High
$38.77
$138.70

Technical Indicators

Market Signals
Indicator
SKE
BLLN
Relative Strength Index (RSI) 48.61 61.90
Support Level $28.14 $79.07
Resistance Level $34.86 $107.00
Average True Range (ATR) 1.46 7.80
MACD -0.15 0.91
Stochastic Oscillator 33.43 71.51

Price Performance

Historical Comparison
SKE
BLLN

About SKE Skeena Resources Limited

Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: